| Trial ID # | NCT03598270; ANITA |
| Phase | III |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-L1 |
| Drug Name | Atezolizumab |
| Alternate Drug Names | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A , MPDL3280A, RG7446 |
| Drugs in Trial | Atezolizumab, Carboplatin, Gemcitabine, Liposomal doxorubicin, Niraparib, Paclitaxel |
| Eligible Participant | Platinum sensitive ovarian cancer at first or second recurrence |
| Patients Enrolled | 417 |
| Therapy Setting | Recurrence |
| Study Design | Double Blind, Randomized |
| Endpoints | ORR, PFS, evaluated per RECIST |
| Biomarkers | PD-L1 status |
| Efficacy | CarboPt+Gem/Pac/PLD+Aze w/Nir+Aze maint (n=209) vs CarboPt+Gem/Pac/PLD+Placebo w/ Nir+Placebo maint (n=208): ORR: 45 vs 43% PD-L1+: PD-L1-: |
| Clinically Significant Adverse Events | CarboPt+Gem/Pac/PLD+Aze w/Nir+Aze maint vs CarboPt+Gem/Pac/PLD+Placebo w/ Nir+Placebo maint: |
| Conclusion | Combining atezolizumab with chemotherapy and maintenance niraparib for platinum sensitive recurrent OC does not significantly improve ORR or PFS; no difference in treatment effect according to PD-L1 status |
| Reference | Gonzalez-Martin A et al. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. J Clin Oncol (2024) |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.